The North America Male Infertility Market is expected to witness market growth of 6.9% CAGR during the forecast period (2020-2026).
There is a gradual rise in the rates of global infertility in both developed and developing countries. Changing habits, delayed pregnancy, and aging are some of the factors behind global cases of infertility. Various techniques like DNA fragmentation, oxidative stress, CASA (computer-assisted semen analysis), sperm penetration assay, sperm agglutination, and microscopic examination are being used to diagnose infertility in males. DNA fragmentation is a new technique that has already gained popularity and is recognized as a standard technique in developing countries. The technique has yet to gain popularity in developing regions and is still to be used as a routine technique due to the cost impediment.
The DNA fragmentation method is predicted to have witnessed a healthy growth in the future due to a high degree of acceptance and the potential of diagnostic procedures to provide a reliable analysis of the integrity of sperm DNA. As DNA aggregation of sperm is one of the key reasons causing male infertility. This method was used for medical purposes in the determination of male infertility.
Continuous R&D efforts are being made to better understand the idiopathic world of infertility. As a result, companies are investing in the development of root cause identification and targeted treatment devices. In addition, the production and commercialization of hormonal therapy are expected to fuel the demand for male infertility during the forecast period. Governments in different countries have taken steps to boost the recovery scenario for infertility-related therapies. In addition, improved safety of patient data due to standardization of legislation is expected to increase consumer demand for infertility treatment.
Based on Treatment, the market is segmented into Assisted Reproductive Technology & Varicocele Surgery and Medication. Based on Test, the market is segmented into DNA Fragmentation Technique, Oxidative Stress Analysis, Computer Assisted Semen Analysis, Microscopic Examination, Sperm Agglutination, Sperm Penetration Assay and Other Tests. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Sanofi S.A., Bayer AG, Cadila Healthcare Ltd. (Zydus Cadila), Endo International PLC, Aytu BioScience, Inc., Vitrolife AB, SCSA Diagnostics, Inc., Andrology Solutions Limited, Halotech DNA SL, and Intas Pharmaceutical Ltd.
Scope of the Study
Market Segmentation:
By Treatment
By Tests
By Country
Companies Profiled
Unique Offerings from the Publisher
There is a gradual rise in the rates of global infertility in both developed and developing countries. Changing habits, delayed pregnancy, and aging are some of the factors behind global cases of infertility. Various techniques like DNA fragmentation, oxidative stress, CASA (computer-assisted semen analysis), sperm penetration assay, sperm agglutination, and microscopic examination are being used to diagnose infertility in males. DNA fragmentation is a new technique that has already gained popularity and is recognized as a standard technique in developing countries. The technique has yet to gain popularity in developing regions and is still to be used as a routine technique due to the cost impediment.
The DNA fragmentation method is predicted to have witnessed a healthy growth in the future due to a high degree of acceptance and the potential of diagnostic procedures to provide a reliable analysis of the integrity of sperm DNA. As DNA aggregation of sperm is one of the key reasons causing male infertility. This method was used for medical purposes in the determination of male infertility.
Continuous R&D efforts are being made to better understand the idiopathic world of infertility. As a result, companies are investing in the development of root cause identification and targeted treatment devices. In addition, the production and commercialization of hormonal therapy are expected to fuel the demand for male infertility during the forecast period. Governments in different countries have taken steps to boost the recovery scenario for infertility-related therapies. In addition, improved safety of patient data due to standardization of legislation is expected to increase consumer demand for infertility treatment.
Based on Treatment, the market is segmented into Assisted Reproductive Technology & Varicocele Surgery and Medication. Based on Test, the market is segmented into DNA Fragmentation Technique, Oxidative Stress Analysis, Computer Assisted Semen Analysis, Microscopic Examination, Sperm Agglutination, Sperm Penetration Assay and Other Tests. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Sanofi S.A., Bayer AG, Cadila Healthcare Ltd. (Zydus Cadila), Endo International PLC, Aytu BioScience, Inc., Vitrolife AB, SCSA Diagnostics, Inc., Andrology Solutions Limited, Halotech DNA SL, and Intas Pharmaceutical Ltd.
Scope of the Study
Market Segmentation:
By Treatment
- Assisted Reproductive Technology & Varicocele Surgery and
- Medication
By Tests
- DNA Fragmentation Technique
- Oxidative Stress Analysis
- Computer Assisted Semen Analysis
- Microscopic Examination
- Sperm Agglutination
- Sperm Penetration Assay and
- Other Tests
By Country
- US
- Canada
- Mexico
- Rest of North America
Companies Profiled
- Sanofi S.A.
- Bayer AG
- Cadila Healthcare Ltd. (Zydus Cadila)
- Endo International PLC
- Aytu BioScience, Inc.
- Vitrolife AB
- SCSA Diagnostics, Inc.
- Andrology Solutions Limited
- Halotech DNA SL
- Intas Pharmaceutical Ltd.
Unique Offerings from the Publisher
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. North America Male Infertility Market by Treatment
Chapter 4. North America Male Infertility Market by Test
Chapter 5. North America Male Infertility Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Sanofi S.A.
- Bayer AG
- Cadila Healthcare Ltd. (Zydus Cadila)
- Endo International PLC
- Aytu BioScience, Inc.
- Vitrolife AB
- SCSA Diagnostics, Inc.
- Andrology Solutions Limited
- Halotech DNA SL
- Intas Pharmaceutical Ltd.
Methodology
LOADING...
